Daniel Ahn, DO
Hematology & Oncology · Scottsdale, AZNPI 1669633897
Payments from drug & device makers
Across 265 payments — averaging $34,500 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6.2M
- Bayer$1.4M
- Incyte Corporation$635K
- Mirati Therapeutics, Inc.$493K
- Taiho Oncology, Inc.$173K
- Redhill Biopharma Inc.$146K
- plus $105K from 14 others
Across 1 payment — averaging $588.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$588
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $6,236,088 |
| Bayer | 54 | $1,355,207 |
| Incyte Corporation | 61 | $634,552 |
| Mirati Therapeutics, Inc. | 18 | $492,533 |
| Taiho Oncology, Inc. | 20 | $172,579 |
| Redhill Biopharma Inc. | 7 | $146,389 |
| Exelixis Inc. | 41 | $26,241 |
| Daiichi Sankyo Company LTD | 3 | $22,120 |
| Alnylam Pharmaceuticals Inc. | 3 | $21,430 |
| Boehringer Ingelheim | 2 | $10,038 |
| Genentech USA, Inc. | 14 | $8,106 |
| Eisai Inc. | 14 | $6,162 |
| Daiichi Sankyo Inc. | 2 | $4,375 |
| Ipsen Biopharmaceuticals, Inc | 5 | $4,276 |
| Advanced Accelerator Applications | 1 | $1,875 |
| Astrazeneca AB | 2 | $188 |
| Tempus AI, Inc | 1 | $127 |
| Pfizer | 1 | $82 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $50 |
| Novartis | 2 | $47 |
How this compares
$9,142,464 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
- Christopher DisimoneScottsdale$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.